CLINICAL_TRIALS ClinicalTrials.gov record update

Benralizumab Regulates Atopic Dermatitis Through Effects on Eosinophils, Basophils and Innate Lymphoid Type 2 Cells.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03563066
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:24.918176+00:00
Published At: 2025-08-22T00:00:00+00:00
Record Updated At: 2025-08-22
Results Posted At: 2025-08-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Dermatitis, Atopic", "Dermatitis", "Eczema", "Skin Diseases", "Skin Diseases, Genetic", "Genetic Diseases, Inborn", "Skin Diseases, Eczematous", "Hypersensitivity", "Hypersensitivity, Immediate", "Immune System Diseases"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-08-22"
protocolSection.identificationModule.nctId: "NCT03563066"
protocolSection.identificationModule.officialTitle: "Benralizumab Regulates Atopic Dermatitis Through Effects on Eosinophils, Basophils and Innate Lymphoid Type 2 Cells."
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-08-22"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.